Change in Age profile of Respiratory Syncytial Virus disease over the course of annual epidemics: a multi-national study.

RSV age surveillance

Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
05 Apr 2024
Historique:
received: 31 12 2023
revised: 16 03 2024
accepted: 29 03 2024
medline: 8 4 2024
pubmed: 8 4 2024
entrez: 7 4 2024
Statut: aheadofprint

Résumé

We aimed to study whether the percentwise age distribution of RSV cases changes over time during annual epidemics. We used surveillance data (2008-2019) from the Netherlands, Lyon (France), Portugal, Singapore, Ecuador, South Africa, and New Zealand. In each country, every season was divided into "epidemic quarters", i.e. periods corresponding to each quartile of RSV cases. Multinomial logistic regression models were fitted to evaluate whether the likelihood of RSV cases being aged <1 or ≥5 years (vs. 1 to <5) changed over time within a season. In all countries, RSV cases were significantly more likely to be aged <1 year in the 4 The age profile of RSV cases shifts within a season, with infants and adolescents, adults, and the elderly constituting a higher proportion of cases in the later phases of annual epidemics. These findings may have implications for RSV prevention policies with newly approved vaccines.

Identifiants

pubmed: 38583722
pii: S0163-4453(24)00088-4
doi: 10.1016/j.jinf.2024.106154
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106154

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: M.B. and R.K. are Sanofi employees and may hold shares and/or stock options in the company. J.P. reports that Nivel has received RSV research grants from the Foundation for Influenza Epidemiology and Sanofi. The remaining authors declare no competing interests. Conflict of interest M.B. and R.K. are Sanofi employees and may hold shares and/or stock options in the company. J.P. reports that Nivel has received RSV research grants from the Foundation for Influenza Epidemiology and Sanofi. The remaining authors declare no competing interests.

Auteurs

Saverio Caini (S)

Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands. Electronic address: s.caini@nivel.nl.

Jean-Sebastien Casalegno (JS)

Virology Department, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, HCL, Lyon, France.

Ana Paula Rodrigues (AP)

Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.

Vernon Lee (V)

Ministry of Health, Singapore.

Cheryl Cohen (C)

Centre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.

Q Sue Huang (QS)

Institute of Environmental Science and Research Limited (ESR), National Centre for Biosecurity and Infectious Disease (NCBID), Upper Hutt, New Zealand.

Alfredo Bruno Caicedo (AB)

Instituto Nacional de Investigación en Salud Pública (INSPI), Centro de Referencia Nacional de Influenza y otros Virus Respiratorios, Guayaquil, Ecuador; Universidad Agraria del Ecuador, Guayaquil, Ecuador.

Anne Teirlinck (A)

National Institute for Public Health and the Environment (RIVM), Centre for Infectious Diseases Research, Bilthoven, the Netherlands.

Raquel Guiomar (R)

Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.

Li Wei Ang (LW)

Ministry of Health, Singapore.

Jocelyn Moyes (J)

Centre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.

Tim Wood (T)

Institute of Environmental Science and Research Limited (ESR), National Centre for Biosecurity and Infectious Disease (NCBID), Upper Hutt, New Zealand.

Doménica de Mora (D)

Instituto Nacional de Investigación en Salud Pública (INSPI), Centro de Referencia Nacional de Influenza y otros Virus Respiratorios, Guayaquil, Ecuador.

Mathieu Bangert (M)

Sanofi Pasteur, Lyon, France.
Virology Department, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, HCL, Lyon, France.

Rolf Kramer (R)

Sanofi Pasteur, Lyon, France.

Lisa Staadegaard (L)

Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands.

Susanne Heemskerk (S)

Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands.

Jojanneke van Summeren (J)

Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands.

Adam Meijer (A)

National Institute for Public Health and the Environment (RIVM), Centre for Infectious Diseases Research, Bilthoven, the Netherlands.

John Paget (J)

Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands.

Classifications MeSH